Biogen Eyes Cambridge Move, Vertex Licenses Alios Drugs, Concert Nabs GSK Payment, & More Boston-Area Life Sciences News

(Page 2 of 2)

the total amount of money raised by the company to $70 million.

—Lexington, MA-based Concert Pharmaceuticals said one of the novel drug candidates in its pipeline nabbed a $4 million milestone payment from GlaxoSmithKline (NYSE: GSK), which is making the molecule its lead drug in an HIV program that it partnered with Concert on in 2009.

—An experimental skin cancer drug developed by Cambridge-based Curis and South San Francisco-based Genentech passed a pivotal clinical trial of 104 patients.

—Waltham, MA-based Tesaro took in a $101 million Series B financing led by Kleiner Perkins Caufield & Byers. The deal also included founding backer New Enterprise Associates, and new investors that include InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Management, and Leerink Swann. Tesaro looks to scoop up drug candidates discovered by other biotechs and further them through clinical development.

Single PageCurrently on Page: 1 2 previous page